Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010

Gary R. Matzke, Thomas C. Dowling, Samantha A. Marks, John E Murphy

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

In 1998, the United States Food and Drug Administration (FDA) released the first guidance for industry regarding pharmacokinetic (PK) studies in renally impaired patients. This study aimed to determine if the FDA renal PK guidance influenced the frequency and rigor of renal studies conducted for new chemical entities (NCEs). FDA-approved package inserts (APIs) and clinical pharmacology review documents were analyzed for 194 NCEs approved from 1999 to 2010. Renal studies were conducted in 71.6% of NCEs approved from 1999 to 2010, a significant increase over the 56.3% conducted from 1996 to 1997 (P =.0242). Renal studies were more likely to be completed in highly renally excreted drugs (fe ≥ 30%) compared with drugs with low renal excretion, fe < 30% (89.6% vs 65.8%, P =.0015). PK studies to assess the impact of dialysis were conducted for 31.7% of NCEs that had a renal study: a greater proportion of high fe NCEs were studied (44.2% vs 26.0%, P =.0335). No significant change in frequency or rigor of PK studies was detected over time. The majority of NCEs (76.3%) with a renal study provided specific dosing recommendations in the API. The adoption of the 1998 FDA guidance has resulted in improved availability of PK and drug-dosing recommendations, particularly for high fe drugs.

Original languageEnglish (US)
Pages (from-to)390-398
Number of pages9
JournalJournal of Clinical Pharmacology
Volume56
Issue number4
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Kidney Diseases
United States Food and Drug Administration
Industry
Kidney
Pharmacokinetics
Pharmaceutical Preparations
Product Labeling
Clinical Pharmacology
Dialysis

Keywords

  • dialysis
  • drug dosing
  • kidney function
  • new chemical entity
  • pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Influence of kidney disease on drug disposition : An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010. / Matzke, Gary R.; Dowling, Thomas C.; Marks, Samantha A.; Murphy, John E.

In: Journal of Clinical Pharmacology, Vol. 56, No. 4, 01.04.2016, p. 390-398.

Research output: Contribution to journalReview article

@article{00733ad4a9d2485484a31194956427fd,
title = "Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010",
abstract = "In 1998, the United States Food and Drug Administration (FDA) released the first guidance for industry regarding pharmacokinetic (PK) studies in renally impaired patients. This study aimed to determine if the FDA renal PK guidance influenced the frequency and rigor of renal studies conducted for new chemical entities (NCEs). FDA-approved package inserts (APIs) and clinical pharmacology review documents were analyzed for 194 NCEs approved from 1999 to 2010. Renal studies were conducted in 71.6{\%} of NCEs approved from 1999 to 2010, a significant increase over the 56.3{\%} conducted from 1996 to 1997 (P =.0242). Renal studies were more likely to be completed in highly renally excreted drugs (fe ≥ 30{\%}) compared with drugs with low renal excretion, fe < 30{\%} (89.6{\%} vs 65.8{\%}, P =.0015). PK studies to assess the impact of dialysis were conducted for 31.7{\%} of NCEs that had a renal study: a greater proportion of high fe NCEs were studied (44.2{\%} vs 26.0{\%}, P =.0335). No significant change in frequency or rigor of PK studies was detected over time. The majority of NCEs (76.3{\%}) with a renal study provided specific dosing recommendations in the API. The adoption of the 1998 FDA guidance has resulted in improved availability of PK and drug-dosing recommendations, particularly for high fe drugs.",
keywords = "dialysis, drug dosing, kidney function, new chemical entity, pharmacokinetics",
author = "Matzke, {Gary R.} and Dowling, {Thomas C.} and Marks, {Samantha A.} and Murphy, {John E}",
year = "2016",
month = "4",
day = "1",
doi = "10.1002/jcph.604",
language = "English (US)",
volume = "56",
pages = "390--398",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Influence of kidney disease on drug disposition

T2 - An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010

AU - Matzke, Gary R.

AU - Dowling, Thomas C.

AU - Marks, Samantha A.

AU - Murphy, John E

PY - 2016/4/1

Y1 - 2016/4/1

N2 - In 1998, the United States Food and Drug Administration (FDA) released the first guidance for industry regarding pharmacokinetic (PK) studies in renally impaired patients. This study aimed to determine if the FDA renal PK guidance influenced the frequency and rigor of renal studies conducted for new chemical entities (NCEs). FDA-approved package inserts (APIs) and clinical pharmacology review documents were analyzed for 194 NCEs approved from 1999 to 2010. Renal studies were conducted in 71.6% of NCEs approved from 1999 to 2010, a significant increase over the 56.3% conducted from 1996 to 1997 (P =.0242). Renal studies were more likely to be completed in highly renally excreted drugs (fe ≥ 30%) compared with drugs with low renal excretion, fe < 30% (89.6% vs 65.8%, P =.0015). PK studies to assess the impact of dialysis were conducted for 31.7% of NCEs that had a renal study: a greater proportion of high fe NCEs were studied (44.2% vs 26.0%, P =.0335). No significant change in frequency or rigor of PK studies was detected over time. The majority of NCEs (76.3%) with a renal study provided specific dosing recommendations in the API. The adoption of the 1998 FDA guidance has resulted in improved availability of PK and drug-dosing recommendations, particularly for high fe drugs.

AB - In 1998, the United States Food and Drug Administration (FDA) released the first guidance for industry regarding pharmacokinetic (PK) studies in renally impaired patients. This study aimed to determine if the FDA renal PK guidance influenced the frequency and rigor of renal studies conducted for new chemical entities (NCEs). FDA-approved package inserts (APIs) and clinical pharmacology review documents were analyzed for 194 NCEs approved from 1999 to 2010. Renal studies were conducted in 71.6% of NCEs approved from 1999 to 2010, a significant increase over the 56.3% conducted from 1996 to 1997 (P =.0242). Renal studies were more likely to be completed in highly renally excreted drugs (fe ≥ 30%) compared with drugs with low renal excretion, fe < 30% (89.6% vs 65.8%, P =.0015). PK studies to assess the impact of dialysis were conducted for 31.7% of NCEs that had a renal study: a greater proportion of high fe NCEs were studied (44.2% vs 26.0%, P =.0335). No significant change in frequency or rigor of PK studies was detected over time. The majority of NCEs (76.3%) with a renal study provided specific dosing recommendations in the API. The adoption of the 1998 FDA guidance has resulted in improved availability of PK and drug-dosing recommendations, particularly for high fe drugs.

KW - dialysis

KW - drug dosing

KW - kidney function

KW - new chemical entity

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84960157851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960157851&partnerID=8YFLogxK

U2 - 10.1002/jcph.604

DO - 10.1002/jcph.604

M3 - Review article

C2 - 26238947

AN - SCOPUS:84960157851

VL - 56

SP - 390

EP - 398

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 4

ER -